Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1

Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 12; no. 16; pp. 4974 - 4982
Main Authors Jose C. Juarez, Oscar Betancourt, Jr, Steven R. Pirie-Shepherd, Xiaojun Guan, Melissa L. Price, David E. Shaw, Andrew P. Mazar, Fernando Doñate
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 15.08.2006
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level. Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro . The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis. Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo . The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic. Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth.
AbstractList Abstract Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level. Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis. Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic. Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth.
Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level. Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro . The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis. Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo . The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic. Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth.
A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level. The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis. ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic. These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth.
PURPOSEA second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level.EXPERIMENTAL DESIGNThe effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis.RESULTSATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic.CONCLUSIONSThese data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth.
Author Jose C. Juarez
Oscar Betancourt, Jr
Andrew P. Mazar
Fernando Doñate
Melissa L. Price
David E. Shaw
Xiaojun Guan
Steven R. Pirie-Shepherd
Author_xml – sequence: 1
  fullname: Jose C. Juarez
– sequence: 2
  fullname: Oscar Betancourt, Jr
– sequence: 3
  fullname: Steven R. Pirie-Shepherd
– sequence: 4
  fullname: Xiaojun Guan
– sequence: 5
  fullname: Melissa L. Price
– sequence: 6
  fullname: David E. Shaw
– sequence: 7
  fullname: Andrew P. Mazar
– sequence: 8
  fullname: Fernando Doñate
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18052150$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16914587$$D View this record in MEDLINE/PubMed
BookMark eNpFkcuO1DAQRS00iHnAJ4C8AYlFBjvxI1k24TXSSCBo1pbjVBKjxG5sR9C_wFfj0I1mVSXr3KryvdfownkHCD2n5JZSXr-hRNYFYVV527ZfCyIKQiV9hK4o57KoSsEvcv-fuUTXMf4ghDJK2BN0SUVDGa_lFfrT-sMBAn5rXW_diLsj3kMKOk3WL34-dr1OgHcpgVtzF_HOjdaP4CDaiLXr8X5dfMAtzDP-EvxsB8hq6x1OU_DrOOUK-M5NtrP_nv2Av615pf9te8DvbFzWpCNg-hQ9HvQc4dm53qDvH97v20_F_eePd-3uvjCsblJRkqbU_cAYGN7UPZiayKHRtAdgtYaBC2qgrFgjiaCV6JrKECOklpXWtBxkdYNeneYegv-5QkxqsdHk-7UDv0YlaslFWW0gP4Em-BgDDOoQ7KLDUVGithDUZrDaDFY5BEWE2kLIuhfnBWu3QP-gOruegZdnQEej5yFoZ2x84GrCS8pJ5l6fuMmO0y8bQJlMQggQQQczKVrmoSp_lVV_AW5Eom8
CitedBy_id crossref_primary_10_3389_fonc_2023_1209156
crossref_primary_10_3390_cancers2010165
crossref_primary_10_1016_j_jinorgbio_2012_07_003
crossref_primary_10_1093_annonc_mds654
crossref_primary_10_1136_vr_100722
crossref_primary_10_18632_oncotarget_4875
crossref_primary_10_3390_ijms21031069
crossref_primary_10_2174_1570164618666210728121529
crossref_primary_10_1016_j_jtemb_2014_07_015
crossref_primary_10_3892_ijo_2014_2396
crossref_primary_10_1074_jbc_R800055200
crossref_primary_10_1038_sj_bjc_6604226
crossref_primary_10_7554_eLife_91611
crossref_primary_10_1016_j_ccr_2020_213635
crossref_primary_10_1038_srep15911
crossref_primary_10_1016_j_freeradbiomed_2013_02_003
crossref_primary_10_1167_iovs_18_25999
crossref_primary_10_1038_s41467_021_22480_x
crossref_primary_10_1158_1078_0432_CCR_08_0315
crossref_primary_10_1016_j_jtemb_2024_127436
crossref_primary_10_1002_dvdy_24285
crossref_primary_10_1124_mol_109_057430
crossref_primary_10_1016_j_ccr_2023_215395
crossref_primary_10_1186_1471_2407_10_375
crossref_primary_10_1016_j_pharmthera_2022_108109
crossref_primary_10_1016_j_mvr_2009_01_003
crossref_primary_10_1007_s00775_014_1107_8
crossref_primary_10_1073_pnas_1113554108
crossref_primary_10_1155_2019_9706792
crossref_primary_10_1093_conphys_coac025
crossref_primary_10_1371_journal_pone_0191607
crossref_primary_10_1038_sj_bjc_6604882
crossref_primary_10_1016_j_bbamcr_2020_118893
crossref_primary_10_1080_10934529_2011_532430
crossref_primary_10_7554_eLife_91611_3
crossref_primary_10_1073_pnas_1513433112
crossref_primary_10_1016_j_ygyno_2011_03_035
crossref_primary_10_1158_1541_7786_MCR_22_0056
crossref_primary_10_1007_s00775_015_1323_x
crossref_primary_10_1021_tx900111y
crossref_primary_10_1097_CMR_0b013e32832c6324
crossref_primary_10_1073_pnas_2023328119
crossref_primary_10_3390_molecules27010148
crossref_primary_10_1017_S0954422419000180
crossref_primary_10_1258_ebm_2011_011267
crossref_primary_10_1507_endocrj_K09E_051
crossref_primary_10_1158_1078_0432_CCR_06_2082
crossref_primary_10_1016_j_canlet_2023_216157
crossref_primary_10_2174_1381612826666200628022113
crossref_primary_10_3389_fonc_2023_1186659
crossref_primary_10_1186_1471_2407_10_9
crossref_primary_10_1080_15548627_2023_2200554
crossref_primary_10_3390_antiox11020427
crossref_primary_10_1159_000438485
crossref_primary_10_3389_fonc_2022_937444
crossref_primary_10_1021_jo1013564
crossref_primary_10_1039_c002439b
crossref_primary_10_1126_science_1179907
crossref_primary_10_1007_s11356_015_5035_0
crossref_primary_10_1016_j_ijbiomac_2023_126684
crossref_primary_10_1016_j_redox_2020_101440
crossref_primary_10_1039_D2DT04060C
crossref_primary_10_1073_pnas_0709451105
crossref_primary_10_1002_adtp_202300198
crossref_primary_10_1038_mto_2015_8
crossref_primary_10_1155_2013_704654
crossref_primary_10_1128_MCB_05722_11
crossref_primary_10_3390_antiox12061159
crossref_primary_10_3390_biomedicines9080852
crossref_primary_10_1158_1078_0432_CCR_17_3705
crossref_primary_10_1039_C5RA03210E
crossref_primary_10_1089_ars_2009_2541
crossref_primary_10_1002_iub_2821
crossref_primary_10_1016_j_cbpa_2016_12_011
crossref_primary_10_3164_jcbn_11_15
crossref_primary_10_1080_10799890903208039
crossref_primary_10_1002_adtp_202000164
crossref_primary_10_1038_nrd2803
crossref_primary_10_1038_s41568_021_00417_2
crossref_primary_10_1038_scibx_2008_421
crossref_primary_10_1038_s41598_018_19873_2
crossref_primary_10_1165_rcmb_2011_0296OC
crossref_primary_10_1158_1535_7163_MCT_18_0667
crossref_primary_10_1021_acsami_7b08347
crossref_primary_10_1016_j_neuroscience_2013_10_033
crossref_primary_10_1111_j_1365_2818_2010_03380_x
crossref_primary_10_18632_oncotarget_23886
crossref_primary_10_1038_s41419_022_05267_w
crossref_primary_10_1158_1078_0432_CCR_12_0697
crossref_primary_10_1016_j_drudis_2015_10_001
crossref_primary_10_1074_jbc_RA118_007095
crossref_primary_10_1534_genetics_113_156836
crossref_primary_10_4049_jimmunol_1700712
crossref_primary_10_1021_jacs_0c06379
crossref_primary_10_3945_an_112_002220
crossref_primary_10_1016_j_urolonc_2011_04_009
crossref_primary_10_1172_JCI71714
crossref_primary_10_1016_j_jcpa_2022_07_002
crossref_primary_10_1016_j_redox_2014_01_001
crossref_primary_10_1126_scisignal_2004870
crossref_primary_10_1371_journal_pone_0071982
crossref_primary_10_1007_s00280_008_0791_x
crossref_primary_10_1002_adtp_201800147
crossref_primary_10_1039_C6SC01272H
crossref_primary_10_1158_1535_7163_MCT_14_0420
crossref_primary_10_3390_biom12101520
crossref_primary_10_1042_BST20140087
crossref_primary_10_1016_j_biopha_2024_116874
crossref_primary_10_1016_j_pneurobio_2014_01_002
crossref_primary_10_1186_1471_2407_12_147
crossref_primary_10_1586_14737140_8_11_1751
crossref_primary_10_1016_j_etap_2017_12_022
crossref_primary_10_1021_jm301053a
crossref_primary_10_1016_j_celrep_2022_110995
crossref_primary_10_1016_j_drup_2023_101018
Cites_doi 10.1073/pnas.87.24.10028
10.1006/cbir.1997.0220
10.1016/S0021-9258(19)85312-7
10.1016/0022-1759(91)90327-C
10.1158/1535-7163.1049.3.9
10.1038/35030140
10.1006/abbi.1998.0618
10.1038/sj.neo.7900218
10.1002/ijc.1565
10.1016/S0891-5849(03)00142-4
10.1177/1534735402238185
10.1073/pnas.1231994100
10.1016/S0024-3205(98)00560-8
10.1038/nm0195-27
10.1152/jappl.1993.74.3.1425
10.1074/jbc.M307146200
10.1038/sj.bjc.6600078
10.1016/0162-0134(84)85008-4
10.1016/0162-0134(86)80011-3
10.1074/jbc.M107711200
10.2174/1568009053765807
10.1016/0014-4827(80)90051-8
10.1073/pnas.89.21.10405
10.1161/01.RES.85.2.147
ContentType Journal Article
Copyright 2006 INIST-CNRS
Copyright_xml – notice: 2006 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1158/1078-0432.CCR-06-0171
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 4982
ExternalDocumentID 10_1158_1078_0432_CCR_06_0171
16914587
18052150
12_16_4974
Genre Journal Article
GroupedDBID -
08R
29B
2WC
34G
39C
3O-
4H-
53G
55
5GY
5RE
5VS
AAPBV
ABFLS
ABOCM
ACIWK
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AETEA
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
GJ
GX1
H13
H~9
IH2
KQ8
L7B
LSO
MVM
O0-
OHT
OK1
P0W
P2P
RCR
RHF
RHI
RNS
SJN
UDS
VH1
W2D
WOQ
X7M
XFK
XJT
ZA5
ZCG
ZGI
---
.55
.GJ
18M
1CY
2FS
476
6J9
AAUGY
ACGFO
ACSVP
ADCOW
ADNWM
AFHIN
AFOSN
AI.
BR6
BTFSW
IQODW
J5H
QTD
TR2
W8F
WHG
YKV
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c489t-2092adf44ec598dec807f9a1dee48aef561ce2349706136b93c0c67a73aa12f73
ISSN 1078-0432
IngestDate Sat Aug 17 02:58:28 EDT 2024
Fri Aug 23 00:41:13 EDT 2024
Thu May 23 23:10:18 EDT 2024
Sun Oct 29 17:07:34 EDT 2023
Fri Jan 15 20:06:54 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 16
Keywords Cell proliferation
Angiogenesis
Enzyme
Superoxide dismutase
Inhibitor
Oxidoreductases
Neovascularization
Copper
Tumor cell
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c489t-2092adf44ec598dec807f9a1dee48aef561ce2349706136b93c0c67a73aa12f73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16914587
PQID 68756237
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_68756237
crossref_primary_10_1158_1078_0432_CCR_06_0171
pubmed_primary_16914587
pascalfrancis_primary_18052150
highwire_cancerresearch_12_16_4974
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 2006-08-15
PublicationDateYYYYMMDD 2006-08-15
PublicationDate_xml – month: 08
  year: 2006
  text: 2006-08-15
  day: 15
PublicationDecade 2000
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2006
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 2022061105054262500_B10
2022061105054262500_B30
2022061105054262500_B17
2022061105054262500_B18
2022061105054262500_B15
2022061105054262500_B16
2022061105054262500_B13
2022061105054262500_B14
2022061105054262500_B11
2022061105054262500_B12
2022061105054262500_B19
2022061105054262500_B20
2022061105054262500_B21
2022061105054262500_B3
2022061105054262500_B28
2022061105054262500_B2
2022061105054262500_B29
2022061105054262500_B1
2022061105054262500_B26
2022061105054262500_B27
2022061105054262500_B7
2022061105054262500_B24
2022061105054262500_B6
2022061105054262500_B25
2022061105054262500_B5
2022061105054262500_B22
2022061105054262500_B4
2022061105054262500_B23
2022061105054262500_B9
2022061105054262500_B8
References_xml – ident: 2022061105054262500_B15
  doi: 10.1073/pnas.87.24.10028
– ident: 2022061105054262500_B8
– ident: 2022061105054262500_B16
  doi: 10.1006/cbir.1997.0220
– ident: 2022061105054262500_B27
  doi: 10.1016/S0021-9258(19)85312-7
– ident: 2022061105054262500_B14
  doi: 10.1016/0022-1759(91)90327-C
– ident: 2022061105054262500_B25
  doi: 10.1158/1535-7163.1049.3.9
– ident: 2022061105054262500_B13
  doi: 10.1038/35030140
– ident: 2022061105054262500_B24
  doi: 10.1006/abbi.1998.0618
– ident: 2022061105054262500_B5
  doi: 10.1038/sj.neo.7900218
– ident: 2022061105054262500_B12
  doi: 10.1002/ijc.1565
– ident: 2022061105054262500_B7
– ident: 2022061105054262500_B17
  doi: 10.1016/S0891-5849(03)00142-4
– ident: 2022061105054262500_B9
  doi: 10.1177/1534735402238185
– ident: 2022061105054262500_B18
  doi: 10.1073/pnas.1231994100
– ident: 2022061105054262500_B29
  doi: 10.1016/S0024-3205(98)00560-8
– ident: 2022061105054262500_B1
  doi: 10.1038/nm0195-27
– ident: 2022061105054262500_B20
  doi: 10.1152/jappl.1993.74.3.1425
– ident: 2022061105054262500_B28
– ident: 2022061105054262500_B30
  doi: 10.1074/jbc.M307146200
– ident: 2022061105054262500_B22
  doi: 10.1038/sj.bjc.6600078
– ident: 2022061105054262500_B10
  doi: 10.1016/0162-0134(84)85008-4
– ident: 2022061105054262500_B11
  doi: 10.1016/0162-0134(86)80011-3
– ident: 2022061105054262500_B26
  doi: 10.1074/jbc.M107711200
– ident: 2022061105054262500_B21
  doi: 10.2174/1568009053765807
– ident: 2022061105054262500_B2
– ident: 2022061105054262500_B4
– ident: 2022061105054262500_B6
– ident: 2022061105054262500_B3
  doi: 10.1016/0014-4827(80)90051-8
– ident: 2022061105054262500_B19
  doi: 10.1073/pnas.89.21.10405
– ident: 2022061105054262500_B23
  doi: 10.1161/01.RES.85.2.147
SSID ssj0014104
Score 2.2950296
Snippet Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently...
A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently...
Abstract Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is...
PURPOSEA second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently...
SourceID proquest
crossref
pubmed
pascalfrancis
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 4974
SubjectTerms Angiogenesis Inhibitors - pharmacology
angiogenesis inhibitors: endogenous and synthetic
Antineoplastic agents
Apoptosis - drug effects
Apoptosis - physiology
Biological and medical sciences
cell growth/signaling pathways
Cell Proliferation - drug effects
Copper - metabolism
Endothelial Cells - drug effects
Endothelial Cells - enzymology
experimental and molecular therapeutics
Humans
Medical sciences
Mitogen-Activated Protein Kinase 1 - metabolism
Mitogen-Activated Protein Kinase 3 - metabolism
Molybdenum - pharmacology
Multiple Myeloma - blood supply
Multiple Myeloma - drug therapy
Multiple Myeloma - enzymology
Multiple Myeloma - pathology
new targets
Pharmacology. Drug treatments
Phosphorylation - drug effects
signal transduction
Superoxide Dismutase - antagonists & inhibitors
Superoxide Dismutase - metabolism
Superoxide Dismutase-1
Title Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1
URI http://clincancerres.aacrjournals.org/content/12/16/4974.abstract
https://www.ncbi.nlm.nih.gov/pubmed/16914587
https://search.proquest.com/docview/68756237
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAviPvKZViIt6ilSZzbIxTQGBog2KS-WbbjrEFtUrWNxPgJ_Cf-G-fEzqVsk4CXtE1Uu833-eSc43Mh5MUkDZTnZ95IMEzJiZkcCeWDzSMCmSWhymSCucPHH8PDU3Y0C2aDwa9e1FK1lWP149K8kv9BFc4Brpgl-w_ItoPCCXgP-MIREIbjX2E8LVcrvXZkblJTUJPUWG12npfLcnEu0Zp3sIBmUaFK6YjiLC_PULrlpjTztlqWawed9xiotcAwF0OIpn0PqqV5Mc9l3miWmwpLi3_PU42bO0sM6daO29dxp02ypUJGrR1bT6j1Ox8BK43fGrcfOjftaw2KqoL_bbZHaip92ijRhg9_zsGuH32dY1yaicg3Pdm6oEcgfC1FZ7kov1XFny6NeGSSOq0UnmDZX2Ydn9pK5gCkoWcaS7Si2-tTtC-IWWKa_1x8QgRx7aywM4yn0y8m8st0gumxZrWsaYPVhFhgtYLd0tzNpWvkuhclAdr-b95_aDexmFt3r2znsglk8AteXjo_FrC1I-5qSU3lagzcFXDfF5lpunK1VVRrRye3yS1r1tBXhqN3yEAXd8mNYxu4cY_8NFSllqpUntOLVKUdVWmfqvAhpTVVKVKV7lCVWqrCq6YdVWmZ0Y6qtKUqde-T03dvT6aHI9sGZKRYnGxhxSeeSDPGtAqSONUqnkRZItxUaxYLnYEFoLTnA-Kom4Yy8dVEhZGIfCFcL4v8B2SvKAu9Tyg8b1yVKj9VIkV0pJvKxMMSiwwMmSgYknFz2_nKVHvhtZUcxBwh4wgZB8g4RoMCZEPyvAGHm0XVrCnuetwNOfJwSA52YOuGrvuJBJMhedbgyEG6460UhS6rDQ_jCA2UaEgeGni771qmPLryymNys1tcT8jedl3pp6BBb-VBzdPf6HDH9A
link.rule.ids 315,786,790,27957,27958
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Copper+binding+by+tetrathiomolybdate+attenuates+angiogenesis+and+tumor+cell+proliferation+through+the+inhibition+of+superoxide+dismutase+1&rft.jtitle=Clinical+cancer+research&rft.au=Juarez%2C+Jose+C&rft.au=Betancourt%2C+Jr%2C+Oscar&rft.au=Pirie-Shepherd%2C+Steven+R&rft.au=Guan%2C+Xiaojun&rft.date=2006-08-15&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=12&rft.issue=16&rft.spage=4974&rft_id=info:doi/10.1158%2F1078-0432.CCR-06-0171&rft_id=info%3Apmid%2F16914587&rft.externalDocID=16914587
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon